Recent News

• 09.08.2025 - Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
• 09.04.2025 - Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.12.2025 - Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
• 05.19.2025 - Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
• 05.14.2025 - Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
• 05.01.2025 - Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Recent Filings

• 08.22.2025 - EFFECT Notice of Effectiveness
• 08.13.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.13.2025 - S-3 Registration statement under Securities Act of 1933
• 08.12.2025 - 8-K Current report
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 8-K Current report
• 05.19.2025 - EX-99.1 EX-99.1